SCHEMBL10275634

SCHEMBL10275634

CCOC(=O)c1c(-c2ccc(C(F)(F)F)nc2)[nH]c2c(-c3ccc(C(F)(F)F)cc3)c(C)nn2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.42
KDM4E B2RXH2 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 1/20 0.39
CNR1 P21554 1/20 0.39
MAPT P10636 6/20 0.38
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.38
HSP90AA1 P07900 1/20 0.38
CRHBP P24387 1/20 0.38
KMT2A Q03164 1/20 0.38
CRHR2 Q13324 1/20 0.38
FOS P01100 1/20 0.38
JUN P05412 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SLC34A1 Q06495 2/20 0.37
ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10313522 0.94 MAPT (0.39) GPR119KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL10275463 0.91 GPR119 (0.44) GPR119KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL10313511 0.88 GPR119 (0.43) GPR119KDM4EL3MBTL1ALDH1A1MAPT
SCHEMBL10276177 0.86 MAPT (0.44) GPR119KDM4EL3MBTL1ALDH1A1MAPT
SCHEMBL10275770 0.86 CNR1 (0.41) GPR119CNR1
SCHEMBL10276317 0.84 ALDH1A1 (0.44) GPR119KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL10313817 0.84 SLC34A1 (0.42) GPR119KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL10276495 0.80 ALDH1A1 (0.44) GPR119KDM4EL3MBTL1ALDH1A1HPGD
SCHEMBL10313477 0.79 CNR1 (0.39) CNR1TSHR
SCHEMBL10275895 0.77 KDM4E (0.45) GPR119KDM4EL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US claimed
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 GPR119 785/4885KDM4E 3483/4885L3MBTL1 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.